Baishan Changbaishan Pharmaceutical Co., Ltd.
-
Founded in:
2001-03-30 -
Country:
China -
Address:
No. 43, West Chang'an Road, Minzhu Street, Jiaohe City, Jilin Province -
Tax NO.:
9122020172313976XT -
Registered Funds:
67.119258 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Raw Aconite |
|
0 | ||
| Raw Aconitum |
|
0 | ||
| Strychnos nux vomica |
|
0 | ||
| Red ginseng |
|
0 | ||
| Cervi Cornu Panto Trichum |
|
0 | ||
| Zaocys |
|
0 | ||
| CARTHAMI FLOS |
|
0 | ||
| MYRRH GUM |
|
9000-45-7 | 0 | |
| Visci Herba |
|
0 | ||
| RHIZOMA ET RADIX NOTOPTERYGII |
|
0 | ||
| Asari Radix et Rhizoma |
|
0 | ||
| DGL |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Acetaminophen |
It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects
More
It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects |
250mg | 103-90-2 | 68 |
| Caffeine |
It is a central nervous system stimulant that can enhance the antipyretic and analgesic effects of acetaminophen and reduce central nervous system inhibitory effects such as drowsiness and dizziness caused by other drugs.
More
It is a central nervous system stimulant that can enhance the antipyretic and analgesic effects of acetaminophen and reduce central nervous system inhibitory effects such as drowsiness and dizziness caused by other drugs. |
15mg | 0 | |
| Chlorphenamine maleate |
It is an antihistamine that can relieve runny nose, nasal congestion, and sneezing symptoms.
More
It is an antihistamine that can relieve runny nose, nasal congestion, and sneezing symptoms. |
1mg | 113-92-8 | 28 |
| Atificial Cow-bezoar |
It has antipyretic and sedative effects
More
It has antipyretic and sedative effects |
10mg | 1002-00-2 | 2 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Furosemide |
1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc.; mainly by inhibiting the active reabsorption of NaCl by the thick wall segment of the renal tubular loop, reducing the osmotic pressure gradient difference of the medullary interstitial fluid, reducing the reabsorption of water, Na+, and Cl-, promoting the excretion of K+ and H+, and increasing the excretion of Ca2+ and Mg2+. Short-term medication can increase uric acid excretion, and long-term medication can cause hyperuricemia. 2. Effect on hemodynamics: Furosemide can inhibit the activity of prostaglandin degrading enzymes, increase the content of prostaglandin E2, dilate blood vessels, reduce renal vascular resistance, and increase renal blood flow; the glomerular filtration rate does not decrease during diuresis; it can also dilate pulmonary capacitance veins, reduce pulmonary capillary permeability, reduce ventricle return blood volume, and reduce left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure and adult respiratory distress syndrome.
More
1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc.; mainly by inhibiting the active reabsorption of NaCl by the thick wall segment of the renal tubular loop, reducing the osmotic pressure gradient difference of the medullary interstitial fluid, reducing the reabsorption of water, Na+, and Cl-, promoting the excretion of K+ and H+, and increasing the excretion of Ca2+ and Mg2+. Short-term medication can increase uric acid excretion, and long-term medication can cause hyperuricemia. 2. Effect on hemodynamics: Furosemide can inhibit the activity of prostaglandin degrading enzymes, increase the content of prostaglandin E2, dilate blood vessels, reduce renal vascular resistance, and increase renal blood flow; the glomerular filtration rate does not decrease during diuresis; it can also dilate pulmonary capacitance veins, reduce pulmonary capillary permeability, reduce ventricle return blood volume, and reduce left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure and adult respiratory distress syndrome. |
54-31-9 | 49 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Compound phenylbutazone |
|
0 | ||
| Spatholobi Caulis |
|
0 |